Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% ...

Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion ...

Shares of VRTX opened at $453.20 on Tuesday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a 52-week low of $377.85 ...

Vertex Pharmaceuticals Incorporated VRTX will release its fourth-quarter financial results, after the closing bell, on Monday, Feb. 10, 2025. Analysts expect the Boston, Massachusetts-based ...

VRTX opened at $462.58 on Tuesday. Vertex Pharmaceuticals has a 1-year low of $377.85 and a 1-year high of $519.88. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to ...

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $533.00. The company’s shares closed ...

Vertex Pharmaceuticals Incorporated VRTX reported mixed results for its fourth quarter on Monday. The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst ...

17:15 EST Vertex Pharmaceuticals (VRTX) files automatic mixed securities shelf Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make ...

VERTEX PHARMACEUTICALS ($VRTX) posted quarterly earnings results on Monday, February 10th. The company reported earnings of $3.98 per share, missing estimates of $4. ...